Want to see SE:BRAIN full AI Analyst Report?
Top Page
BrainCool AB
(BRAIN)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr0.98
▲(13.95% Upside)
Action:Reiterated
Date:09/08/26
The score is held back primarily by weak financial performance—persistent losses, negative gross profit, and significant ongoing cash burn—despite a low-risk balance sheet with zero debt. Technicals are supportive (price above key moving averages with positive MACD), but valuation remains challenging because the company is loss-making and there is no dividend yield data.
Positive Factors
Improving revenue growth
The return to double-digit trailing revenue growth indicates improving commercial traction for BrainCool’s temperature-management offerings. If sustained, broader adoption can expand the installed device base and support recurring consumables demand, creating a foundation for future operating leverage.
Negative Factors
Persistent unprofitability
Negative gross profit and substantial operating losses show that BrainCool has not yet demonstrated a stable, scalable profit model. Continued weak unit economics can limit self-funded growth and make future earnings improvement dependent on materially better pricing, volume, or cost performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving revenue growth
The return to double-digit trailing revenue growth indicates improving commercial traction for BrainCool’s temperature-management offerings. If sustained, broader adoption can expand the installed device base and support recurring consumables demand, creating a foundation for future operating leverage.
Read all positive factors
BrainCool AB (BRAIN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr356.97M
Dividend YieldN/A
Average Volume (3M)473.43K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth6.49%
EPS Growth25.03%
CountrySE
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.12
Shares Outstanding394,878,140
10 Day Avg. Volume773,626
30 Day Avg. Volume473,425
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)kr41.00M
BrainCool AB Business Overview & Revenue Model
Company Description
BrainCool AB (publ), a medical technology company founded in 2010 and headquartered in Lund, Sweden, focuses on the development, commercialization, and distribution of advanced medical cooling systems. Operating with its subsidiaries, the company ...
How the Company Makes Money
BrainCool makes money primarily by selling and/or leasing its temperature management systems to hospitals and other healthcare providers and by generating recurring revenue from disposable consumables and accessories used together with those syste...
BrainCool AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.63M | 36.21M | 39.96M | 23.23M | 17.59M | 9.26M |
| Gross Profit | -26.99M | -40.88M | 13.13M | 12.12M | -46.16M | -48.93M |
| EBITDA | -28.28M | -29.99M | -34.06M | -49.86M | -35.07M | -32.16M |
| Net Income | -34.43M | -37.05M | -44.04M | -61.28M | -45.61M | -38.75M |
Balance Sheet | ||||||
| Total Assets | 170.11M | 192.38M | 162.04M | 133.28M | 133.67M | 99.35M |
| Cash, Cash Equivalents and Short-Term Investments | 43.09M | 39.57M | 31.40M | 25.06M | 41.21M | 13.58M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.00M |
| Total Liabilities | 11.02M | 16.58M | 16.11M | 21.54M | 17.44M | 54.12M |
| Stockholders Equity | 159.10M | 175.80M | 145.93M | 111.74M | 116.23M | 45.23M |
Cash Flow | ||||||
| Free Cash Flow | -49.58M | -56.49M | -70.20M | -67.23M | -53.67M | -35.06M |
| Operating Cash Flow | -49.66M | -52.68M | -62.64M | -61.16M | -46.27M | -24.25M |
| Investing Cash Flow | -2.65M | -6.54M | -7.57M | -6.17M | -7.59M | -10.82M |
| Financing Cash Flow | 85.86M | 67.33M | 76.80M | 50.93M | 81.28M | 36.39M |
BrainCool AB Technical Analysis
Positive
0.86
Price Trends
0.77
Positive
0.77
Positive
0.66
Positive
Market Momentum
0.04
Negative
69.32
Neutral
67.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BRAIN, the sentiment is Positive. The current price of 0.86 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.77, and above the 200-day MA of 0.66, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 69.32 is Neutral, neither overbought nor oversold. The STOCH value of 67.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BRAIN.
BrainCool AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr65.86B | 24.60 | 8.88% | 1.95% | -3.56% | 79.60% | |
71 Outperform | kr8.18B | 92.46 | 4.13% | ― | 8.79% | -20.48% | |
60 Neutral | kr1.35B | -265.81 | -1.22% | ― | 34.05% | -144.96% | |
54 Neutral | kr1.10B | -31.11 | -3.99% | ― | -0.34% | 29.54% | |
52 Neutral | kr356.97M | -7.78 | -22.23% | ― | 6.49% | 25.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | kr408.76M | -8.17 | ― | ― | -2.61% | -0.28% |
* Healthcare Sector Average
SE:BRAIN
BrainCool AB
0.97
0.03
3.41%
SE:GETI.B
Getinge
243.60
36.10
17.40%
SE:PAX
Paxman AB
58.50
-20.10
-25.57%
SE:XVIVO
Xvivo Perfusion AB
264.00
90.60
52.25%
SE:SEDANA
Sedana Medical AB
10.64
-3.12
-22.67%
SE:OSSD
OssDsign AB
3.66
-12.33
-77.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.